Chromadex Stock Price, News & Analysis (NASDAQ:CDXC)

$5.39 +0.01 (+0.19 %)
(As of 02/20/2018 10:13 AM ET)
Previous Close$5.39
Today's Range$5.23 - $5.45
52-Week Range$2.26 - $7.24
Volume287,500 shs
Average Volume537,528 shs
Market Capitalization$290.18 million
P/E Ratio-38.50
Dividend YieldN/A
Beta1.03

About Chromadex (NASDAQ:CDXC)

Chromadex logoChromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

Receive CDXC News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDXC
CUSIPN/A
Phone949-419-0288

Debt

Debt-to-Equity Ratio0.01%
Current Ratio5.03%
Quick Ratio4.12%

Price-To-Earnings

Trailing P/E Ratio-38.4972501964145
Forward P/E Ratio-38.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$26.81 million
Price / Sales10.82
Cash FlowN/A
Price / CashN/A
Book Value$0.26 per share
Price / Book20.73

Profitability

Trailing EPS($0.14)
Net Income$-2,920,000.00
Net Margins-21.89%
Return on Equity-47.30%
Return on Assets-32.25%

Miscellaneous

Employees93
Outstanding Shares53,840,000

Chromadex (NASDAQ:CDXC) Frequently Asked Questions

What is Chromadex's stock symbol?

Chromadex trades on the NASDAQ under the ticker symbol "CDXC."

How were Chromadex's earnings last quarter?

Chromadex Corp (NASDAQ:CDXC) posted its quarterly earnings data on Thursday, August, 11th. The company reported $0.01 earnings per share for the quarter. The company earned $8.80 million during the quarter, compared to analysts' expectations of $6.10 million. Chromadex had a negative net margin of 21.89% and a negative return on equity of 47.30%. View Chromadex's Earnings History.

When will Chromadex make its next earnings announcement?

Chromadex is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for Chromadex.

Where is Chromadex's stock going? Where will Chromadex's stock price be in 2018?

2 equities research analysts have issued 1-year target prices for Chromadex's stock. Their predictions range from $7.00 to $8.00. On average, they expect Chromadex's stock price to reach $7.50 in the next year. View Analyst Ratings for Chromadex.

What are Wall Street analysts saying about Chromadex stock?

Here are some recent quotes from research analysts about Chromadex stock:

  • 1. According to Zacks Investment Research, "ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. " (2/12/2018)
  • 2. HC Wainwright analysts commented, "We note that the company’s revenues came in at $5.3M vs. our original forecast of $8M, while a net loss of $2.7M or $0.07 per share was also recorded vs. our projection for a positive EPS of $0.04. While R&D spending in the quarter was roughly in-line with our estimate at $728K vs. $700K, we note that COGS were slightly worse than our estimate, coming in at 57% vs. our projection of 49%. Given what we see as the current status of ChromaDex’s ingredients business, we have revised our 2017 revenue number to $24.3M, while we now project a net loss per share for 2017 of $0.14 vs. our prior forecast for EPS of $0.16 for the year." (8/11/2017)

Who are some of Chromadex's key competitors?

Who are Chromadex's key executives?

Chromadex's management team includes the folowing people:

  • Stephen Allen, Independent Chairman of the Board (Age 67)
  • Robert N. Fried, President, Chief Strategy Officer, Chief Operating Officer, Director (Age 58)
  • Frank L. Jaksch Jr., Chief Executive Officer, Independent Director (Age 48)
  • Kevin M. Farr CPA, Chief Financial Officer, Secretary, Principal Accounting Officer and Principal Financial Officer (Age 59)
  • Troy Rhonemus, Executive Vice President (Age 44)
  • Mark Friedman, General Counsel and Corporate Secretary
  • Andrew Johnson, Director of Investor Relations, IR Contact Officer
  • Tony Lau, Director
  • Steven D. Rubin Esq. J.D., Director (Age 56)
  • Wendy Yu, Director

Who owns Chromadex stock?

Chromadex's stock is owned by a number of of institutional and retail investors. Top institutional investors include Tieton Capital Management LLC (1.06%), Millennium Management LLC (1.01%), North Star Investment Management Corp. (0.28%), BlackRock Inc. (0.21%), Wells Fargo & Company MN (0.10%) and Renaissance Technologies LLC (0.08%). Company insiders that own Chromadex stock include Frank L Jaksch Jr, River Ventures Ltd Champion, Robert N Fried, Step Holdings Ltd Pioneer, Stephen R Allen and Troy Allen Rhonemus. View Institutional Ownership Trends for Chromadex.

Who sold Chromadex stock? Who is selling Chromadex stock?

Chromadex's stock was sold by a variety of institutional investors in the last quarter, including North Star Investment Management Corp. and Tieton Capital Management LLC. View Insider Buying and Selling for Chromadex.

Who bought Chromadex stock? Who is buying Chromadex stock?

Chromadex's stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Oppenheimer & Co. Inc., Wells Fargo & Company MN, Cetera Advisor Networks LLC, Two Sigma Investments LP, Monashee Investment Management LLC and Deutsche Bank AG. Company insiders that have bought Chromadex stock in the last two years include Frank L Jaksch Jr, River Ventures Ltd Champion, Robert N Fried, Step Holdings Ltd Pioneer, Stephen R Allen and Troy Allen Rhonemus. View Insider Buying and Selling for Chromadex.

How do I buy Chromadex stock?

Shares of Chromadex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chromadex's stock price today?

One share of Chromadex stock can currently be purchased for approximately $5.39.

How big of a company is Chromadex?

Chromadex has a market capitalization of $290.18 million and generates $26.81 million in revenue each year. The company earns $-2,920,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Chromadex employs 93 workers across the globe.

How can I contact Chromadex?

Chromadex's mailing address is 10005 Muirlands Blvd. Suite G, IRVINE CA, 92618. The company can be reached via phone at 949-419-0288 or via email at [email protected]


MarketBeat Community Rating for Chromadex (CDXC)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  116 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  207
MarketBeat's community ratings are surveys of what our community members think about Chromadex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Chromadex (NASDAQ:CDXC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.50$7.50$6.33$5.50
Price Target Upside: 44.79% upside21.36% upside47.29% upside89.00% upside

Chromadex (NASDAQ:CDXC) Consensus Price Target History

Price Target History for Chromadex (NASDAQ:CDXC)

Chromadex (NASDAQ:CDXC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2018HC WainwrightSet Price TargetBuy$8.00HighView Rating Details
9/25/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$7.00N/AView Rating Details
1/3/2017Rodman & RenshawInitiated CoverageBuy$6.00N/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Chromadex (NASDAQ:CDXC) Earnings History and Estimates Chart

Earnings by Quarter for Chromadex (NASDAQ:CDXC)

Chromadex (NASDAQ CDXC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018($0.03)N/AView Earnings Details
11/9/2017Q3 2017($0.05)($0.07)$6.50 million$6.09 millionViewN/AView Earnings Details
8/10/2017Q2 2017$0.04($0.05)$11.00 million$5.31 millionViewN/AView Earnings Details
5/11/2017Q1 2017$0.01($0.05)$8.00 million$4.45 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.01)($0.06)$5.60 million$5.64 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.03)$5.01 millionViewListenView Earnings Details
8/11/2016Q216$0.01$6.10 million$8.80 millionViewListenView Earnings Details
5/12/2016Q116$0.01$5.30 million$7.30 millionViewListenView Earnings Details
3/17/2016Q4 2015($0.03)$4.36 millionViewN/AView Earnings Details
5/14/2015Q1 2015($0.03)$5.26 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.03)$4.14 millionViewN/AView Earnings Details
8/12/2014Q2 2014($0.06)$3.86 millionViewN/AView Earnings Details
5/8/2014Q1 2014($0.06)$3.07 millionViewN/AView Earnings Details
11/21/2013Q3 13($0.01)$2.72 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.03)$2.71 millionViewN/AView Earnings Details
5/10/2013Q1 2013$0.03$2.34 millionViewN/AView Earnings Details
3/29/2013Q4 2012($0.06)ViewN/AView Earnings Details
11/8/2012Q3 2012($0.06)($0.06)ViewN/AView Earnings Details
8/9/2012Q2 2012($0.12)($0.13)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.09)($0.16)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.09)($0.10)ViewN/AView Earnings Details
11/10/2011Q3 2011($0.09)($0.10)ViewN/AView Earnings Details
8/11/2011Q2 2011($0.08)ViewN/AView Earnings Details
5/12/2011Q1 2011($0.05)ViewN/AView Earnings Details
3/16/2011Q4 2010($0.03)ViewN/AView Earnings Details
11/16/2010Q3 2010($0.03)ViewN/AView Earnings Details
8/17/2010Q2 2010($0.02)ViewN/AView Earnings Details
3/31/2010Q4 2009($0.01)ViewN/AView Earnings Details
11/17/2009Q3 2009($0.02)ViewN/AView Earnings Details
8/18/2009Q2 2009($0.03)ViewN/AView Earnings Details
5/15/2009Q1 2009($0.03)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Chromadex (NASDAQ:CDXC) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.14 EPS
Next Year EPS Consensus Estimate: $0.07 EPS

Dividends

Dividend History for Chromadex (NASDAQ:CDXC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Chromadex (NASDAQ CDXC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.59%
Institutional Ownership Percentage: 6.00%
Insider Trades by Quarter for Chromadex (NASDAQ:CDXC)
Institutional Ownership by Quarter for Chromadex (NASDAQ:CDXC)

Chromadex (NASDAQ CDXC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/11/2018Frank L Jaksch JrCEOSell28,379$6.52$185,031.08View SEC Filing  
12/21/2017Frank L Jaksch JrCEOSell58,400$6.19$361,496.00View SEC Filing  
11/17/2017River Ventures Ltd ChampionMajor ShareholderBuy731,707$4.10$2,999,998.70View SEC Filing  
8/25/2017Stephen R AllenDirectorBuy2,000$3.31$6,620.007,000View SEC Filing  
8/18/2017Step Holdings Ltd PioneerMajor ShareholderBuy786,167$2.60$2,044,034.20View SEC Filing  
8/15/2017Robert N FriedInsiderBuy10,000$3.15$31,500.00583,241View SEC Filing  
5/24/2017Step Holdings Ltd PioneerMajor ShareholderBuy2,521,526$2.60$6,555,967.60View SEC Filing  
5/19/2017Stephen R AllenDirectorBuy3,000$3.20$9,600.005,000View SEC Filing  
3/20/2017Stephen R AllenDirectorBuy2,000$2.81$5,620.002,000View SEC Filing  
12/12/2016Frank L Jaksch JrCEOBuy2,000$2.42$4,840.00201,557View SEC Filing  
9/1/2016Frank L Jaksch JrCEOBuy1,500$3.32$4,980.00199,557View SEC Filing  
9/1/2016Robert N FriedDirectorBuy15,000$3.39$50,850.0066,979View SEC Filing  
6/20/2016Troy Allen RhonemusCOOBuy7,800$3.47$27,066.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Chromadex (NASDAQ CDXC) News Headlines

Source:
DateHeadline
Two Additional Collaborative Human Studies on NIAGEN® with the University of Cambridge and the University of Washington Now Registered on Clinical-trials.gov.Two Additional Collaborative Human Studies on NIAGEN® with the University of Cambridge and the University of Washington Now Registered on Clinical-trials.gov.
finance.yahoo.com - February 20 at 9:04 AM
BRIEF-Chromadex Chairman Stephen Allen Will Retire From The BoardBRIEF-Chromadex Chairman Stephen Allen Will Retire From The Board
www.reuters.com - February 17 at 8:58 AM
ChromaDex (CDXC) Chairman Stephen Allen to Retire from Board of DirectorsChromaDex (CDXC) Chairman Stephen Allen to Retire from Board of Directors
www.streetinsider.com - February 17 at 8:58 AM
ChromaDex Chairman Stephen Allen Will Retire from Board of DirectorsChromaDex Chairman Stephen Allen Will Retire from Board of Directors
finance.yahoo.com - February 16 at 4:37 PM
Chromadex (CDXC) Cut to Sell at Zacks Investment ResearchChromadex (CDXC) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - February 12 at 7:18 PM
ChromaDex (CDXC) Reports Prelim. 4Q Revenues Above Consensus, Prelim. FY18 Revenues Expected Below EstimatesChromaDex (CDXC) Reports Prelim. 4Q Revenues Above Consensus, Prelim. FY18 Revenues Expected Below Estimates
www.streetinsider.com - February 12 at 9:06 AM
ChromaDex Corporation Reports Preliminary 2017 Results   ChromaDex Corporation Reports Preliminary 2017 Results   
finance.yahoo.com - February 12 at 9:06 AM
Chromadex (CDXC) Upgraded at BidaskClubChromadex (CDXC) Upgraded at BidaskClub
www.americanbankingnews.com - February 11 at 9:36 AM
Chromadex (CDXC) Given a $8.00 Price Target by HC Wainwright AnalystsChromadex (CDXC) Given a $8.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - February 10 at 4:44 PM
Chromadex (CDXC) Lifted to Hold at ValuEngineChromadex (CDXC) Lifted to Hold at ValuEngine
www.americanbankingnews.com - February 8 at 11:14 PM
National Institutes of Health (NIH) Announces NIAGEN® Prevents Neurological Damage and Shows Improved Cognitive and Physical Function in a Mouse Model of Alzheimer’s DiseaseNational Institutes of Health (NIH) Announces NIAGEN® Prevents Neurological Damage and Shows Improved Cognitive and Physical Function in a Mouse Model of Alzheimer’s Disease
finance.yahoo.com - February 8 at 8:53 AM
ChromaDex to Present at the 3rd Annual NAD+ SummitChromaDex to Present at the 3rd Annual NAD+ Summit
finance.yahoo.com - February 1 at 9:16 AM
Chromadex (CDXC) Lowered to "Sell" at BidaskClubChromadex (CDXC) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - January 27 at 3:58 PM
ChromaDex (CDXC) Reports Denial by PTAB of Elysium Healths Challenge of ChromaDex Licensed 807 Patent - StreetInsider.comChromaDex (CDXC) Reports Denial by PTAB of Elysium Health's Challenge of ChromaDex Licensed '807' Patent - StreetInsider.com
www.streetinsider.com - January 23 at 8:15 AM
ChromaDex Appoints Mark Friedman as General Counsel and Corporate Secretary - GlobeNewswire (press release)ChromaDex Appoints Mark Friedman as General Counsel and Corporate Secretary - GlobeNewswire (press release)
globenewswire.com - January 23 at 8:15 AM
ChromaDex Appoints Mark Friedman as General Counsel and Corporate SecretaryChromaDex Appoints Mark Friedman as General Counsel and Corporate Secretary
finance.yahoo.com - January 23 at 8:15 AM
BRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Healths Request To Invalidate U.S. PatentBRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Health's Request To Invalidate U.S. Patent
www.reuters.com - January 22 at 5:52 PM
Elysium Health, Inc. Challenge of ChromaDex Licensed Patent Denied by Patent Trial and Appeal Board (PTAB)Elysium Health, Inc. Challenge of ChromaDex Licensed Patent Denied by Patent Trial and Appeal Board (PTAB)
finance.yahoo.com - January 22 at 5:52 PM
Chromadexs (CDXC) Buy Rating Reiterated at HC WainwrightChromadex's (CDXC) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - January 16 at 8:08 AM
Head-To-Head Contrast: Portola Pharmaceuticals (PTLA) vs. Chromadex (CDXC)Head-To-Head Contrast: Portola Pharmaceuticals (PTLA) vs. Chromadex (CDXC)
www.americanbankingnews.com - January 13 at 5:06 PM
Insider Selling: Chromadex Corp (CDXC) CEO Sells 28,379 Shares of StockInsider Selling: Chromadex Corp (CDXC) CEO Sells 28,379 Shares of Stock
www.americanbankingnews.com - January 12 at 6:58 PM
Wired News – ChromaDex Launched TRU NIAGEN(TM) in Singapore with Retail Partner WatsonsWired News – ChromaDex Launched TRU NIAGEN(TM) in Singapore with Retail Partner Watsons
finance.yahoo.com - January 10 at 10:00 AM
ChromaDex and Watsons Expand Partnership with TRU NIAGEN™ Retail Launch in SingaporeChromaDex and Watsons Expand Partnership with TRU NIAGEN™ Retail Launch in Singapore
finance.yahoo.com - January 8 at 9:29 AM
Chromadex (CDXC) vs. Its Competitors Head-To-Head ContrastChromadex (CDXC) vs. Its Competitors Head-To-Head Contrast
www.americanbankingnews.com - December 30 at 1:18 PM
Insider Selling: Chromadex Corp (CDXC) CEO Sells 58,400 Shares of StockInsider Selling: Chromadex Corp (CDXC) CEO Sells 58,400 Shares of Stock
www.americanbankingnews.com - December 26 at 5:36 PM
Critical Review: Chromadex (CDXC) vs. Its PeersCritical Review: Chromadex (CDXC) vs. Its Peers
www.americanbankingnews.com - December 25 at 11:42 PM
Chromadex (CDXC) and Its Competitors Head-To-Head SurveyChromadex (CDXC) and Its Competitors Head-To-Head Survey
www.americanbankingnews.com - December 23 at 5:24 PM
Chromadex (CDXC) Cut to Buy at BidaskClubChromadex (CDXC) Cut to Buy at BidaskClub
www.americanbankingnews.com - December 23 at 2:56 PM
Chromadex Corp (CDXC) Given Consensus Recommendation of "Buy" by BrokeragesChromadex Corp (CDXC) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 23 at 1:52 AM
Reviewing Chromadex (CDXC) & The CompetitionReviewing Chromadex (CDXC) & The Competition
www.americanbankingnews.com - December 22 at 7:27 PM
ChromaDex (CDXC) vs. Momenta Pharmaceuticals (MNTA) Financial ComparisonChromaDex (CDXC) vs. Momenta Pharmaceuticals (MNTA) Financial Comparison
www.americanbankingnews.com - December 21 at 9:28 AM
Contrasting ChromaDex (CDXC) and Its CompetitorsContrasting ChromaDex (CDXC) and Its Competitors
www.americanbankingnews.com - December 19 at 7:10 PM
BRIEF-Chromadex Files For Resale Of Up To 5.6 Mln Shares Of Common Stock By The Selling StockholdersBRIEF-Chromadex Files For Resale Of Up To 5.6 Mln Shares Of Common Stock By The Selling Stockholders
www.reuters.com - December 14 at 5:30 PM
Published Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac Function ... - NasdaqPublished Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac Function ... - Nasdaq
www.nasdaq.com - December 14 at 10:03 AM
Published Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac Function in an Animal Model of Heart FailurePublished Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac Function in an Animal Model of Heart Failure
finance.yahoo.com - December 14 at 10:03 AM
ChromaDex (CDXC) Says Nicotinamide Riboside Shown in Published Research to Improve Mitochondrial Energy ... - StreetInsider.comChromaDex (CDXC) Says Nicotinamide Riboside Shown in Published Research to Improve Mitochondrial Energy ... - StreetInsider.com
www.streetinsider.com - December 10 at 9:50 AM
Analyzing ChromaDex (CDXC) and The CompetitionAnalyzing ChromaDex (CDXC) and The Competition
www.americanbankingnews.com - December 9 at 7:18 PM
Nicotinamide Riboside Shown to Improve Mitochondrial Energy Production and Memory in Alzheimer’s Disease ResearchNicotinamide Riboside Shown to Improve Mitochondrial Energy Production and Memory in Alzheimer’s Disease Research
finance.yahoo.com - December 8 at 9:55 AM
ChromaDex (CDXC) Downgraded by ValuEngine to "Sell"ChromaDex (CDXC) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - December 3 at 7:58 PM
ChromaDex (CDXC) Lowered to Hold at Zacks Investment ResearchChromaDex (CDXC) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - November 29 at 6:04 PM
ChromaDex (CDXC) Raised to "Buy" at Zacks Investment ResearchChromaDex (CDXC) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - November 28 at 6:30 PM
Zacks: Analysts Set $6.50 Target Price for ChromaDex Corporation (CDXC)Zacks: Analysts Set $6.50 Target Price for ChromaDex Corporation (CDXC)
www.americanbankingnews.com - November 28 at 5:36 AM
ChromaDex Corporation (CDXC) Price Target Raised to $8.00ChromaDex Corporation (CDXC) Price Target Raised to $8.00
www.americanbankingnews.com - November 27 at 4:44 PM
 Analysts Set $6.50 Target Price for ChromaDex Corporation (CDXC) Analysts Set $6.50 Target Price for ChromaDex Corporation (CDXC)
www.americanbankingnews.com - November 21 at 7:33 PM
ChromaDex Corporation (CDXC) Major Shareholder Acquires $2,999,998.70 in StockChromaDex Corporation (CDXC) Major Shareholder Acquires $2,999,998.70 in Stock
www.americanbankingnews.com - November 21 at 1:33 PM
Head-To-Head Analysis: ChromaDex Corporation (CDXC) vs. Advaxis (ADXS)Head-To-Head Analysis: ChromaDex Corporation (CDXC) vs. Advaxis (ADXS)
www.americanbankingnews.com - November 17 at 3:34 AM
Investors Buy High Volume of ChromaDex Corporation Call Options (CDXC)Investors Buy High Volume of ChromaDex Corporation Call Options (CDXC)
www.americanbankingnews.com - November 16 at 2:06 AM
ChromaDex Corporation Sees Unusually Large Options Volume (CDXC)ChromaDex Corporation Sees Unusually Large Options Volume (CDXC)
www.americanbankingnews.com - November 16 at 2:06 AM
ChromaDexs (CDXC) CEO Frank Jaksch on Q1 2016 Results - Earnings Call TranscriptChromaDex's (CDXC) CEO Frank Jaksch on Q1 2016 Results - Earnings Call Transcript
seekingalpha.com - May 16 at 6:13 PM
CHROMADEX CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitsCHROMADEX CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - May 16 at 6:12 AM

SEC Filings

Chromadex (NASDAQ:CDXC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Chromadex (NASDAQ CDXC) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.